Zentalis is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression
Zentalis is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression. WEE1 kinase inhibition is a novel approach that breaks down the safeguards that cancer cells use to survive.